Song Jianping, Liu Yanfeng, Chen Qian, Yang Jinhuan, Jiang Zhengchen, Zhang Hao, Liu Zhaojian, Jin Bin
Department of General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250112, P.R. China.
Department of Oncology, Qilu Hospital of Shandong University, Jinan, Shandong 250112, P.R. China.
Oncol Lett. 2019 Apr;17(4):3851-3861. doi: 10.3892/ol.2019.10054. Epub 2019 Feb 19.
Suppressor of variegation, Enhancer of Zeste, Trithorax and Myeloid-Nervy-DEAF1 domain-containing (SMYD) proteins are a set of lysine methyltransferases involved in a range of diverse biological functions, including gene expression, and regulation of skeletal and cardiac-muscle development. These proteins may additionally serve roles in a number of different types of cancer. However, the roles of the five SMYD proteins, SMYD 1/2/3/4/5, their expression patterns and prognostic value remain unclear. In the present study, the transcriptional expression levels of the five SMYD proteins were compared with the survival data of patients with breast carcinoma (BC) from the ONCOMINE dataset, Breast Cancer Gene-Expression Miner v4.0, Kaplan-Meier Plotter, The Cancer Genome Atlas and cBioPortal. An increase in the SMYD2/3/5 mRNA expression levels and a decrease in SMYD1/4 mRNA expression levels in BC tissues compared with normal tissues were identified. Increased SMYD3 mRNA and decreased SMYD5 mRNA expression levels were associated with decreased levels of histological differentiation, according to the Scarff-Bloom-Richardson grading system. Kaplan-Meier curves demonstrated that the increased SMYD1/4 and decreased SMYD2/3 mRNA expression levels were associated with good relapse-free survival (RFS) in patients with BC. Furthermore, SMYD2 mRNA expression levels were associated with the RFS of patients with BC with metastatic relapse, and SMYD4 may serve as a tumor suppressor in patients with BC, as patients with increased SMYD4 mRNA expression levels had significantly better RFS compared with decreased SMYD4 mRNA expression levels. The present data suggested that SMYD2 and SMYD3 may be potential biomarkers for diagnosis of BC. Additionally, SMYD2 and SMYD4 may be potential prognostic indicators of patients with BC.
含异染色质抑制因子、zeste增强子、三体胸段蛋白和髓系-神经-耳聋1结构域（SMYD）的蛋白质是一组赖氨酸甲基转移酶，参与一系列不同的生物学功能，包括基因表达以及骨骼和心肌发育的调节。这些蛋白质可能在多种不同类型的癌症中也发挥作用。然而，五种SMYD蛋白，即SMYD 1/2/3/4/5的作用、它们的表达模式和预后价值仍不清楚。在本研究中，将这五种SMYD蛋白的转录表达水平与来自ONCOMINE数据集、乳腺癌基因表达挖掘器v4.0、Kaplan-Meier绘图仪、癌症基因组图谱和cBioPortal的乳腺癌（BC）患者的生存数据进行了比较。与正常组织相比，BC组织中SMYD2/3/5 mRNA表达水平升高，SMYD1/4 mRNA表达水平降低。根据斯卡夫-布鲁姆-理查森分级系统，SMYD3 mRNA表达增加和SMYD5 mRNA表达降低与组织学分化水平降低有关。Kaplan-Meier曲线表明，SMYD1/4 mRNA表达增加和SMYD2/3 mRNA表达降低与BC患者良好的无复发生存期（RFS）相关。此外，SMYD2 mRNA表达水平与发生转移复发的BC患者的RFS相关，并且SMYD4可能在BC患者中作为肿瘤抑制因子发挥作用，因为与SMYD4 mRNA表达水平降低的患者相比，SMYD4 mRNA表达水平升高的患者RFS明显更好。目前的数据表明，SMYD2和SMYD3可能是BC诊断的潜在生物标志物。此外，SMYD2和SMYD4可能是BC患者的潜在预后指标。
